Hoping for the green path, prepared for the red path.
1 Hour RSI, Stock, and MAC dont look too good, but on the Daily chart they look great!
The market is bullish and the idea is to invest in the Market direction. Fundamental Analysis Info: Britain is in talks with Swiss drugmaker Roche Holding AG (ROG.S) to buy an accurate COVID-19 antibody test, following the lead of the European Union and United States, which had already given preliminary approval to the tests.
Parameters : Position Size : %1 Risk/Reward Ratio : 3 Stop-Loss : 275 Goal : 284.2 *** NOTE : If opens too high , Goal is 290.8.
On Friday, Swiss pharmaceutical company Roche (RHHBY) announced it received emergency approval from the U.S. Food and Drug Administration for the use of its new diagnostic test for Covid-19, the disease caused by the novel coronavirus that was first identified in China near the end of 2019. More specifically, the test kit can be used to detect cells of the virus...
Dates in the future with the highest probability for price direction reversals
Dates in the future with the highest probability for price direction reversals
Dates in the future with the highest probability for price direction reversals
RHHBY has seen two previous bump and run formations and is looking for a continuation with a third bump and run, indicated by the green fractal. These bumps form above the natural trend and a bearish reversal slowly follows. Again I recommend ‘Encyclopedia of Chart patterns’ By TN Bulkowski for anyone interested in learning some patterns.
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro...
AVERAGE ANALYSTS PRICE TARGET $38 AVERAGE ANALYSTS RECOMMENDATION overweight P/E RATIO 19 SHORT INTEREST COMPANY PROFILE Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology,...
Could consolidate a little but has a priority review PDUFA date of 8/18/19 for Enrectinib solid tumors and ROSI-positive non-small cell lung cancer. Also PDUFA date of 9/2/19 for Tecentriq plus chemo
buy opportunity its a pullback to s/r zone and there is a nice trigger on daily time